Table 3.

Statistical models of included studies.

Source	Model	Cut-off	Adjusted risk estimates	Unadjusted risk estimates	No. of covariates	Other platelet function tests	Other independent predictors from multivariable analysis
Tscharre et al. (26)	U&M Cox ph	IPC > 7,600/μL	HR, 1.693 (95% CI, 1.156, 2.481)	HR, 1.716 (95% CI, 1.152, 2.559)	31	MEA, VASP-P, MPV	Age, hyperlipidemia, peripheral artery disease, ACEI or ARB, DES
Ibrahim et al. (31)	M Cox ph	IPC > 7,632/μL	HR, 4.65 (95% CI, 1.78, 12.16)	N/A	7	MPV, LTA	N/A
Perl et al. (30)	M regression	IPF% > median	OR, 1.968 (95% CI, 1.1128–3.432)	N/A	15	MPV	Age, prior MI, anemia
López-Jiménez et al. (28)	M regression	IPF% > 6.2%	OR, 2.42 (95% CI, 1.08, 5.43)	N/A	5	N/A	Admittance Killip
Cesari et al. (29)	U&M regression	IPF% > 3.3%	OR, 2.83 (95% CI, 1.14–7.06)	OR, 4.15 (95% CI, 1.24–13.91)	8	MPV, LTA, H-IPF	H-IPF
Freynhofer et al. (27)	U&M regression	IPF% > 3.35%	OR, 1.136 (95% CI, 1.001–1.288)	OR, 1.173 (95% CI, 1.040–1.324)	41	MEA, VASP-P, MPV	Troponin I, CRP, prior MI

M regression, multivariable logistic regression analysis; U&M regression, univariable and multivariable logistic regression analysis; U&M Cox ph, univariable and multivariable Cox proportional hazard analysis; M Cox ph, multivariable Cox proportional hazard analysis; HR, hazard ratio; OR, odds ratio; CI, confidence interval; MPV, mean platelet volume; H-IPF, highly fluorescent immature platelet fraction; MEA, multiple electrode aggregometry; LTA, light transmission aggregometry; VASP-P, vasodilator-stimulated phosphoprotein-phosphorylation; ACEI, angiotensin-converting-enzyme inhibitors; ARB, angiotensin II receptor blockers; DES, drug eluting stent; CRP, C-reactive protein.